TARA — Protara Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1359931 ·
Last close
$2.32
Market Cap
$137.10M
52W High
$7.82
52W Low
$2.09
ADV30
905,942
Next earnings
2026-11-06

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -23,154,000 -21,688,000 156,541,000 25,150,000 15,518,000
Jun 2026 0 — -23,324,000 -21,668,000 176,093,000 17,076,000 14,782,000
Mar 2026 0 — -19,629,000 -17,782,000 191,923,000 14,737,000 10,715,000
Dec 2025 0 — -19,079,000 -17,307,000 209,468,000 49,657,000 13,056,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-66,134,000
Investing CF
$-30,381,000
Financing CF
$82,095,000
CapEx
$-94,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-341,869,000
Inventory
—
Receivables
$1,277,000
ST Investments
$125,418,000
EBIT TTM
$-76,792,000
Pretax Income TTM
$-70,015,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -64,549,000 -57,439,000 209,468,000 13,056,000 196,412,000 -56,365,000
Dec 2024 0 -49,154,000 -44,596,000 181,454,000 14,320,000 167,134,000 -35,808,000
Dec 2023 0 -43,613,000 -40,420,000 78,954,000 10,633,000 68,321,000 -37,557,000
Dec 2022 0 -37,545,000 -65,952,000 113,290,000 11,207,000 102,083,000 -26,457,000

TTM Snapshot

Revenues TTM
$6,528,000
NetIncome TTM
$-70,015,000
OpCashFlow TTM
—
Assets (Latest)
$176,093,000
Forward EPS
$-1.69

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.34 · call volume: 50 · put volume: 8
Expected Move to 2027-02-19: ±$1.15 (49.15%) — implied range $1.19 – $3.49 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HUMA Humacyte, Inc. $139.18M $0.50 —
STRO SUTRO BIOPHARMA, INC. $148.08M $8.92 —
IPHA Innate Pharma SA $148.56M $1.33 —
IVVD Invivyd, Inc. $151.09M $0.51 —
FATE FATE THERAPEUTICS INC $124.00M $1.02 —

News headlines (Yahoo Finance, 1h cache)

Protara Therapeutics: Q3 Earnings Snapshot
2026-11-06 13:06 · Yahoo
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
2026-11-06 13:00 · Yahoo
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
2026-10-15 12:00 · Yahoo
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 20:05 · Yahoo
What Makes Protara Therapeutics (TARA) a New Buy Stock
2026-07-21 16:00 · Yahoo
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
2026-05-15 11:00 · Yahoo
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
2026-04-27 20:05 · Yahoo
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
2026-05-20 12:00 · Yahoo
One Protara Therapeutics Insider Raised Their Stake In The Previous Year
2026-05-04 10:15 · Yahoo
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
2026-08-11 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.